Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer

INTRODUCTION: The potential of oncogene-driven targeted therapy is perhaps most fully realized in non-small cell lung cancer (NSCLC), given the number of genomic targets and approved matched therapies. However, invasive tissue biopsy at the time of each disease progression may not be possible and is...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Autores principales: Villaflor, Victoria, Won, Brian, Nagy, Rebecca, Banks, Kimberly, Lanman, Richard B., Talasaz, AmirAli, Salgia, Ravi
Formato: Artigo
Lenguaje:Inglês
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5341844/
https://ncbi.nlm.nih.gov/pubmed/27602770
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.11801
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares